Targeting UBR5 blunts tumor-induced immunosuppression and improves the response to anti-PD-1 antibodies by preventing intratumoral infiltration of TAMs, one of the most important players in shaping the TME in OC. The gene discussed is UBR5; the disease is neoplasm.